Haemonetics/$HAE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Haemonetics
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
- Ticker
- $HAE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 3,009
- Headquarters
- Boston, United States
- Website
- www.haemonetics.com
Haemonetics Metrics
BasicAdvanced
$5.5B
58.91
$2.06
0.52
-
Price and volume
Market cap
$5.5B
Beta
0.52
52-week high
$123.77
52-week low
$48.62
Average daily volume
683K
Financial strength
Current ratio
3.08
Quick ratio
1.674
Long term debt to equity
1.397
Total debt to equity
1.403
Interest coverage (TTM)
9.30%
Profitability
EBITDA (TTM)
358.786
Gross margin (TTM)
59.33%
Net profit margin (TTM)
7.12%
Operating margin (TTM)
18.85%
Effective tax rate (TTM)
26.18%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
6.60%
Return on equity (TTM)
11.20%
Valuation
Price to earnings (TTM)
58.909
Price to revenue (TTM)
4.171
Price to book
6.59
Price to tangible book (TTM)
-21.69
Price to free cash flow (TTM)
19.363
Free cash flow yield (TTM)
5.16%
Free cash flow per share (TTM)
6.264
Growth
Revenue change (TTM)
0.44%
Earnings per share change (TTM)
-37.17%
3-year revenue growth (CAGR)
3.53%
10-year revenue growth (CAGR)
4.09%
3-year earnings per share growth (CAGR)
-8.20%
10-year earnings per share growth (CAGR)
4.77%
What the Analysts think about Haemonetics
Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.
Analyst projections of the future price of Haemonetics stock.
Bulls say / Bears say
Fiscal Q1 2027 revenue rose 5.6% and organic revenue grew 5.9%. Haemonetics then raised its full-year revenue growth outlook to 5–8%, signalling stronger near-term momentum. (Haemonetics, The Motley Fool)
Plasma organic revenue grew 8.2% in Q1, supported by share gains and strong disposable sales. CSL expects to roll out Haemonetics’ collection systems across its current US centres by the end of 2027, offering a further growth opportunity. (The Motley Fool, StockTitan)
The Hospital business is showing strength across both franchises: Blood Management Technologies grew on higher volume and share gains, while Interventional Technologies returned to growth in Q1. This could reduce the company’s reliance on plasma as a growth engine. (Haemonetics, The Motley Fool)
Blood Center is a drag on the outlook: management expects mid-single-digit revenue declines in FY27 as it continues to rationalise the portfolio. This offsets some of the expected growth in Plasma and Hospital. (MarketScreener, The Motley Fool)
The CSL opportunity is not yet a firm revenue commitment: the agreement has no minimum purchases, and the rollout’s scope and timing can change. Haemonetics has not yet incorporated an estimated impact into its FY27 guidance. (StockTitan, MassDevice)
Profit growth is lagging sales: Q1 net income fell 3% year on year despite revenue rising 5.6%. The company also had about $951 million of net debt at quarter end, limiting financial flexibility. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
Haemonetics Financial Performance
Revenues and expenses
Haemonetics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Haemonetics News
AllArticlesVideos
Funds containing Haemonetics
AllEURGBPUSD
Fund name | Fund size | $HAE weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.18% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.18% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.16% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.16% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.